Figure 4.
ACR70 response and remission rates (based on DAS28<2.6) for tofacitinib, baricitinib and upadacitinib in RA patients who have failed one or more bDMARDs.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.